Erschienen in:
13.11.2017 | Letter to the Editor
Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib
verfasst von:
Ahmet Emre Eskazan
Erschienen in:
International Journal of Clinical Oncology
|
Ausgabe 2/2018
Einloggen, um Zugang zu erhalten
Excerpt
With the advent of imatinib—the first tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia (CML)—managing patients with CML in the chronic phase (CML-CP) has changed dramatically. Second-generation TKIs (2GTKIs) are more potent than imatinib and can be a better option. Nilotinib and dasatinib were superior to imatinib regarding speed and depth of responses, with no significant benefit in long-term outcomes, including progression-free and overall survivals (PFS and OS) over imatinib in the frontline setting [
1]. …